secwatch.observer — SEC 8-K summary
======================================

Issuer:     ADC Therapeutics SA (ADCT)
CIK:        0001771910
Form:       8-K
Filed at:   2025-03-27T23:59:59+00:00
Accession:  0001628280-25-015057
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ADC Therapeutics reports Q4/FY2024 results: net loss narrows; ZYNLONTA revenue flat; cash runway to H2 2026
--------------------------------------------------------------------------------

- Net loss Q4 2024 was $30.7M ($0.29/share) vs $85.0M ($1.03) in Q4 2023; full year net loss $157.8M ($1.62) vs $240.1M ($2.94).
- ZYNLONTA net product revenue $16.4M in Q4 and $69.3M for FY 2024, roughly flat vs prior year.
- Cash $250.9M at Dec 31, 2024; runway into H2 2026 after $97.4M May 2024 offering.
- LOTIS-5 Phase 3 confirmatory trial enrollment completed Dec 2024; data update expected late 2025.
- LOTIS-7 Phase 1b: 94% best ORR and 72% CR in r/r DLBCL; dose expansion enrollment completing Q2 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1771910/000162828025015057/0001628280-25-015057-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1771910/000162828025015057/adc-20250327.htm
  HTML page:      https://secwatch.observer/filing/0001628280-25-015057

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer